id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC9386120 | core_pubmed_pmc | The effect of phenobarbital treatment on behavioral comorbidities and on the composition and function of the fecal microbiome in dogs with idiopathic epilepsy | The effect of phenobarbital treatment on behavioral comorbidities and on the composition and function of the fecal microbiome in dogs with idiopathic epilepsy Abstract Phenobarbital (PB) is one of the most important antiseizure drugs (ASDs) to treat canine idiopathic epilepsy (IE). The effect of PB on the taxonomic cha... |
PMC12853878 | core_pubmed_pmc | Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents | Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents Abstract Abstract Background and objective With the redefinition of the EUCAST ‘I’ susceptibility category, from ‘intermediate’ to... |
PMC11561580 | core_pubmed_pmc | Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using Pharmacokinetic-Pharmacodynamic Simulations | Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using Pharmacokinetic-Pharmacodynamic Simulations Abstract Abstract Background Artemether-lumefantrine is the most widely used treatment for uncomplicated malaria and it is dosed based on weight bands according to World Health Organizati... |
PMC9715596 | core_pubmed_pmc | Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder | Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder Abstract Abstract The severity of the ongoing opioid crisis, recently exacerbated by the COVID-19 pandemic, emphasizes the importance for individuals suffering from opioid use disorder (OUD) to have access to and receive efficacious, ev... |
PMC6598480 | core_pubmed_pmc | Effects of puerarin on the pharmacokinetics of triptolide in rats | Effects of puerarin on the pharmacokinetics of triptolide in rats Abstract Abstract Context: Puerarin and triptolide are sometimes used together for the treatment of disease in Chinese clinics; however, the drug–drug interaction between puerarin and triptolide is still unknown. Objective: This study investigates the ef... |
PMC9257044 | core_pubmed_pmc | Therapeutic Drug Monitoring of Ceftazidime-Avibactam Concentrations in Carbapenem-Resistant K. pneumoniae- Infected Patients With Different Kidney Statuses | Therapeutic Drug Monitoring of Ceftazidime-Avibactam Concentrations in Carbapenem-Resistant K. pneumoniae- Infected Patients With Different Kidney Statuses Abstract Aims: Carbapenem-resistant K. pneumoniae (CRKP) is the most common carbapenem-resistant Enterobacteriaceae with high mortality. Ceftazidime-avibactam (CAZ-... |
PMC8241022 | core_pubmed_pmc | Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit | Controllable continuous sub-tenon drug delivery of dexamethasone disodium phosphate to ocular posterior segment in rabbit Abstract Abstract Corticosteroids have been used for treatment of posterior segment eye diseases, but the delivery of drug to the posterior segments is still a problem to resolve. In our study, we e... |
PMC12780488 | core_pubmed_pmc | An Overview of Liquid Chromatography–Mass Spectrometry (LC–MS) Methods for the Quantification of Antibody‐Drug Conjugates | An Overview of Liquid Chromatography–Mass Spectrometry (LC–MS) Methods for the Quantification of Antibody‐Drug Conjugates Abstract ABSTRACT Antibody‐drug conjugates (ADCs) are innovative drugs composed of cytotoxic molecules (payload) linked to antibodies, that selectively target and kill cancer cells upon internalizat... |
PMC6154486 | core_pubmed_pmc | Pharmacokinetic and pharmacodynamic studies of etodolac loaded vesicular gels on rats by transdermal delivery | Pharmacokinetic and pharmacodynamic studies of etodolac loaded vesicular gels on rats by transdermal delivery Abstract Background The present study includes the development of liposomal and ethosomal gels for transdermal delivery to overcome the side effects associated with oral route. Methods The liposomes and ethosom... |
PMC12084224 | core_pubmed_pmc | Artificial intelligence generated 3D body composition predicts dose modifications in patients undergoing neoadjuvant chemotherapy for rectal cancer | Artificial intelligence generated 3D body composition predicts dose modifications in patients undergoing neoadjuvant chemotherapy for rectal cancer Abstract Purpose Chemotherapy administration is a balancing act between giving enough to achieve the desired tumour response while limiting adverse effects. Chemotherapy do... |
PMC5582369 | core_pubmed_pmc | Tenapanor administration and the activity of the H + ‐coupled transporter PepT1 in healthy volunteers | Tenapanor administration and the activity of the H + ‐coupled transporter PepT1 in healthy volunteers Abstract Aim Tenapanor (RDX5791/AZD1722), an inhibitor of gastrointestinal Na + /H + exchanger NHE3, is being evaluated for the treatment of patients with constipation‐predominant irritable bowel syndrome and the treat... |
PMC12943722 | core_pubmed_pmc | Physiologically Based Pharmacokinetic Modelling of Hydroxyurea in Patients with Sickle Cell Disease: A Special Focus on Lactating Women and Breastfed Infants to Inform Safe Dosing and Breastfeeding Strategies | Physiologically Based Pharmacokinetic Modelling of Hydroxyurea in Patients with Sickle Cell Disease: A Special Focus on Lactating Women and Breastfed Infants to Inform Safe Dosing and Breastfeeding Strategies Abstract Abstract Background/Objectives : Hydroxyurea is currently the standard disease-modifying therapy for r... |
PMC10786959 | core_pubmed_pmc | A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir | A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir Abstract Abstract Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus di... |
PMC12630006 | core_pubmed_pmc | Influence of Potential Pharmacodynamic Drug Interactions in Pharmacotherapy of Coronary Heart Disease with Comorbid Conditions on Treatment Adherence: A Cross-Sectional Study of a Ukrainian Patient Cohort | Influence of Potential Pharmacodynamic Drug Interactions in Pharmacotherapy of Coronary Heart Disease with Comorbid Conditions on Treatment Adherence: A Cross-Sectional Study of a Ukrainian Patient Cohort Abstract Purpose Coronary heart disease (CHD) is accompanied by a high level of comorbidity, which necessitates the... |
PMC12656350 | core_pubmed_pmc | Arzanol: A Review of Chemical Properties and Biological Activities | Arzanol: A Review of Chemical Properties and Biological Activities Abstract Abstract Arzanol, a prenylated phloroglucinol–α-pyrone heterodimer, displays a broad range of pharmacological properties. This review compiles findings from 2007 to 2025 on its chemistry, conformational behavior, bioactivities, molecular target... |
PMC4461093 | core_pubmed_pmc | Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections | Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections Abstract Drug-resistant pathogens have gained a foothold especially in the most vulnerable patient populations, hospitalized and immunocompromised individuals. Furthermore, extended-spectrum β-lactamase and ca... |
PMC9011188 | core_pubmed_pmc | Ivermectin Plasma Concentration in Iberian Ibex ( Capra pyrenaica ) Following Oral Administration: A Pilot Study | Ivermectin Plasma Concentration in Iberian Ibex ( Capra pyrenaica ) Following Oral Administration: A Pilot Study Abstract Sarcoptic mange is considered the main driver of demographic declines occurred in the last decades in Iberian ibex ( Capra pyrenaica ) populations. Mass treatment campaigns by administration of in-f... |
PMC6681021 | core_pubmed_pmc | Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism | Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism Abstract This study investigated the pharmacokinetics of tofacitinib in rats and the effects of first-pass metabolism on tofacitinib pharmacokinetics. Intravenous administration of 5, 10, 20, and 50 mg/kg t... |
PMC12645405 | core_pubmed_pmc | Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation | Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation Abstract Purpose Lamotrigine demonstrates substantial interindividual pharmacokinetic variability during pregnancy, though the underlying mechanisms remain incompletely understood. The study aimed to develop a population... |
PMC12358299 | core_pubmed_pmc | Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLME | Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLME Abstract ABSTRACT Keizer initially described Pirana as a workbench designed to streamline management of NONMEM modeling, visualization, and analysis. Initial versions of Pirana integrated tools included NONMEM and PSN. As new tools have... |
PMC3834941 | core_pubmed_pmc | Pharmacokinetic Evaluation of a DSPE-PEG 2000 Micellar Formulation of Ridaforolimus in Rat | Pharmacokinetic Evaluation of a DSPE-PEG 2000 Micellar Formulation of Ridaforolimus in Rat Abstract The rapamycin analog, ridaforolimus, has demonstrated potent anti-proliferative effects in cancer treatment, and it currently is being evaluated in a range of clinical cancer studies. Ridaforolimus is an extremely lipoph... |
PMC4440724 | core_pubmed_pmc | Robust and Reproducible Quantification of the Extent of Chest Radiographic Abnormalities (And It’s Free!) | Robust and Reproducible Quantification of the Extent of Chest Radiographic Abnormalities (And It’s Free!) Abstract Abstract Rationale Objective, reproducible quantification of the extent of abnormalities seen on a chest radiograph would improve the user-friendliness of a previously proposed severity scoring system for ... |
PMC5207541 | core_pubmed_pmc | VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients | VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients Abstract Abstract Vitamin K antagonists (VKAs) are highly effective but have a narrow therapeutic index and require routine monitoring of the INR. The primary aim of pharmacogenetics (PGx) is to optimize patient ... |
PMC11897418 | core_pubmed_pmc | The Single‐Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs | The Single‐Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs Abstract ABSTRACT Levetiracetam (LEV) is an anti‐epileptic drug used extra‐label in dogs. Commercially available extended‐release formulations (LEV‐ER), administered twice daily, can... |
PMC9010270 | core_pubmed_pmc | Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes | Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes Abstract Abstract Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present... |
PMC10235566 | core_pubmed_pmc | Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs | Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs Abstract Abstract The neurosteroid allopregnanolone (ALLO) is under investigation as a treatment for benzodiazepine‐refractory status epilepticus (SE). Here, we assess the cardiopulmonary safety... |
PMC5056674 | core_pubmed_pmc | Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults | Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults Abstract A previously presented physiologically-based pharmacokinetic model for immediate release (IR) methylphenidate (MPH) was extended to characterize the ... |
PMC7877841 | core_pubmed_pmc | Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities | Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities Abstract T‐cell directing/engaging bispecifics (TDBs) enable a powerful mode of action by activating T‐cells through the creation of artificial immune synapses. Their pharmacological response involves the dynamic i... |
PMC5209692 | core_pubmed_pmc | A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application | A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application Abstract Abstract In the field of cardiac drug efficacy and safety assessment, information on drug concentration in heart tissue is desirable. Because measuring drug concentrations in human cardiac tissue is challe... |
PMC12201673 | core_pubmed_pmc | Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions | Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions Abstract The success of mRNA vaccines against infectious diseases such as COVID-19 has opened new avenues for their application in oncology. In cancer immunotherapy, mRNA vaccines—typically encapsulated in lipid nanoparti... |
PMC6373417 | core_pubmed_pmc | Development and In Vivo Evaluation of Ziyuglycoside I–Loaded Self-Microemulsifying Formulation for Activity of Increasing Leukocyte | Development and In Vivo Evaluation of Ziyuglycoside I–Loaded Self-Microemulsifying Formulation for Activity of Increasing Leukocyte Abstract Ziyuglycoside I (ZgI), a major effective ingredient of Sanguisorba officinalis L, has shown good activity in increasing leukocyte of myelosuppression mice. However, oral ZgI thera... |
PMC8560717 | core_pubmed_pmc | Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides | Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides Abstract Antisense oligonucleotides (ASOs) containing bridged nucleic acids (BNAs) have been proven to be very powerful. However, ensuring a reliable discovery and translational development scheme for this class of... |
PMC10010323 | core_pubmed_pmc | TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies | TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies Abstract Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in a su... |
PMC8449800 | core_pubmed_pmc | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment Abstract Depot medroxyprogesterone acetate is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculos... |
PMC12812941 | core_pubmed_pmc | Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations | Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations Abstract Introduction Escitalopram (S-CIT) is commonly prescribed for depression and anxiety in older patients. Previous research has reported that the effect of CYP2C19 polymorphism on S-CIT pharmacokinetics is more pronoun... |
PMC5856878 | core_pubmed_pmc | Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer | Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer Abstract Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. P... |
PMC11458338 | core_pubmed_pmc | Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model | Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model Abstract This study aimed to estimate individual pharmacokinetic (PK) parameters in an obese hemodialysis (HD) patient receiving gentamicin and to assess the impact of obesity on gentamicin... |
PMC7132596 | core_pubmed_pmc | UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats | UPLC–MS/MS assay for quantification of an inhibitor of kinases (Foretinib) in plasma: Application to a pharmacokinetic study in rats Abstract Abstract Foretinib, an oral multikinase inhibitor, is known to have anti-tumor effects against cancers. The doses and the levels of foretinib vary based on the type of cancer to ... |
PMC11434788 | core_pubmed_pmc | Development, Stability, and In Vitro/In Vivo Studies of Volatile Oil Pickering Emulsion Stabilized by Modified Amber | Development, Stability, and In Vitro/In Vivo Studies of Volatile Oil Pickering Emulsion Stabilized by Modified Amber Abstract Volatile oil stabilization strategies based on encapsulation with a large number of excipients limit further applications. The primary objective of this study is to improve the stability of vola... |
PMC11098163 | core_pubmed_pmc | Population longitudinal analysis of Gait Profile Score and North Star Ambulatory Assessment in children with Duchenne muscular dystrophy | Population longitudinal analysis of Gait Profile Score and North Star Ambulatory Assessment in children with Duchenne muscular dystrophy Abstract Abstract Duchenne muscular dystrophy (DMD) is a rare X‐linked recessive disorder characterized by loss‐of‐function mutations in the gene encoding dystrophin. These mutations ... |
PMC5591805 | core_pubmed_pmc | Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis | Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis Abstract Purpose The aims of this study were to characterize the concentration–time course of cladribine (CdA) and its main metabolite 2-chloroadenine (CAde), estimate interindividual variability in pharmacokinetics (PK), and identify covaria... |
PMC11504871 | core_pubmed_pmc | Target Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive Staphylococcus aureus Infections: A Prospective Cohort Study | Target Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive Staphylococcus aureus Infections: A Prospective Cohort Study Abstract This study aimed to determine cefazolin target attainment in patients with invasive Staphylococcus aureus ( S. aureus ) infections and to develop a population ph... |
PMC11502491 | core_pubmed_pmc | Minimum effective dose of clemastine in a mouse model of preterm white matter injury | Minimum effective dose of clemastine in a mouse model of preterm white matter injury Abstract Background Preterm white matter injury (PWMI) is the most common cause of brain injury in premature neonates. PWMI involves a differentiation arrest of oligodendrocytes, the myelinating cells of the central nervous system. Cle... |
PMC10333628 | core_pubmed_pmc | Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective | Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective Abstract Abstract Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to poorly understood disease etiology, unpredictable disease progression, highly heterogeneous patient populations, and a lack of rob... |
PMC10222093 | core_pubmed_pmc | Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure | Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure Abstract Abstract Levonorgestrel (LNG) is a progestin used in many contraceptive formulations, including subcutaneous implants. There is an unmet need for developing long-acting formulations for LNG. To devel... |
PMC7187405 | core_pubmed_pmc | The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial | The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial Abstract Abstract This study compared the pharmacokinetic (PK) profile of a new liquid formulation of mepolizumab with the established lyophilized formulatio... |
PMC7983940 | core_pubmed_pmc | Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm | Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm Abstract Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direc... |
PMC8184152 | core_pubmed_pmc | Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study | Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study Abstract Abstract Background Management of acute exacerbations of chronic obstructive pulmonary disease (COPD) is sometimes inadequate leading to either prolonged duration and/or an increased risk of recurrent exacerbatio... |
PMC6166769 | core_pubmed_pmc | Mechanisms and the clinical relevance of complex drug–drug interactions | Mechanisms and the clinical relevance of complex drug–drug interactions Abstract As a result of an increasing aging population, the number of individuals taking multiple medications simultaneously has grown considerably. For these individuals, taking multiple medications has increased the risk of undesirable drug–drug ... |
PMC6067669 | core_pubmed_pmc | Plasma concentrations of fenbendazole (FBZ) and oxfendazole in alpacas ( Lama pacos ) after single intravenous and oral dosing of FBZ | Plasma concentrations of fenbendazole (FBZ) and oxfendazole in alpacas ( Lama pacos ) after single intravenous and oral dosing of FBZ Abstract The objective of this study was to determine plasma pharmacokinetics and bioavailability of fenbendazole (FBZ) and oxfendazole (OFZ) after intravenous (iv) and oral administrati... |
PMC6264278 | core_pubmed_pmc | Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes | Corydaline Inhibits Multiple Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes Abstract Abstract Corydaline is a bioactive alkaloid with various antiacetylcholinesterase, antiallergic, and antinociceptive activities found in the medicinal herb Corydalis Tubers. The inhibitory p... |
PMC12461970 | core_pubmed_pmc | Enoxolone pharmacokinetics, tissue distribution, and residue depletion in largemouth bass ( Micropterus salmoides ) | Enoxolone pharmacokinetics, tissue distribution, and residue depletion in largemouth bass ( Micropterus salmoides ) Abstract Enoxolone, a hydrolyzed component of Chinese herbal medicine, has shown efficacy against Flavobacterium columnare in largemouth bass ( Micropterus salmoides ). However, its pharmacokinetics and m... |
PMC10187109 | core_pubmed_pmc | Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis | Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis Abstract ABSTRACT Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis ... |
PMC10144056 | core_pubmed_pmc | Application of Computing as a High-Practicability and -Efficiency Auxiliary Tool in Nanodrugs Discovery | Application of Computing as a High-Practicability and -Efficiency Auxiliary Tool in Nanodrugs Discovery Abstract Research and development (R&D) of nanodrugs is a long, complex and uncertain process. Since the 1960s, computing has been used as an auxiliary tool in the field of drug discovery. Many cases have proven the ... |
PMC11962430 | core_pubmed_pmc | Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients | Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients Abstract Background Tacrolimus, an approved first-line calcineurin inhibitor, is widely prescribed in organ transplantation to prevent allograft rejection. Its narrow therapeutic index requires precise management to a... |
PMC3494424 | core_pubmed_pmc | Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours | Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours Abstract Background: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human xenograft tumour models.... |
PMC2875439 | core_pubmed_pmc | Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes | Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes Abstract Abstract OBJECTIVE To determine the pharmacokinetic and pharmacodynamic properties of an oral insulin (OI) formulation compared with subcutaneously injected regular human insulin (RHI). RESEARCH DESIGN AND METHO... |
PMC11179697 | core_pubmed_pmc | Comparison of dose selection based on target engagement versus inhibition of receptor–ligand interaction for checkpoint inhibitors | Comparison of dose selection based on target engagement versus inhibition of receptor–ligand interaction for checkpoint inhibitors Abstract Abstract Immune checkpoint inhibitors block the interaction between a receptor on one cell and its ligand on another cell, thus preventing the transduction of an immunosuppressive ... |
PMC10820138 | core_pubmed_pmc | Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis | Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis Abstract Abstract Exploring the influence of pyrazinamide exposure and susceptibility on treatment response is crucial for optimizing the management of multidrug-... |
PMC7518978 | core_pubmed_pmc | Engineered tissues and strategies to overcome challenges in drug development | Engineered tissues and strategies to overcome challenges in drug development Abstract Abstract Current preclinical studies in drug development utilize high-throughput in vitro screens to identify drug leads, followed by both in vitro and in vivo models to predict lead candidates' pharmacokinetic and pharmacodynamic pro... |
PMC4070457 | core_pubmed_pmc | Determination of Oral Bioavailability of Fusaric Acid in Male Sprague-Dawley Rats | Determination of Oral Bioavailability of Fusaric Acid in Male Sprague-Dawley Rats Abstract Head and neck squamous cell cancer accounts for 3 % of new cancer cases and 2 % of cancer mortality annually in the United States. Current treatment options for most head and neck cancers continue to be surgical excision with or ... |
PMC12706424 | core_pubmed_pmc | A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe | A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe Abstract ABSTRACT Efavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of mult... |
PMC5012553 | core_pubmed_pmc | Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model | Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model Abstract Abstract Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The use of this tool as a treatment mod... |
PMC11448508 | core_pubmed_pmc | Therapeutic antibodies in oncology: an immunopharmacological overview | Therapeutic antibodies in oncology: an immunopharmacological overview Abstract Abstract The biotechnological development of monoclonal antibodies and their immunotherapeutic use in oncology have grown exponentially in the last decade, becoming the first-line therapy for some types of cancer. Their mechanism of action i... |
PMC11463156 | core_pubmed_pmc | Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b | Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b Abstract Abstract Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the trea... |
PMC12683211 | core_pubmed_pmc | Advances in Conductive Nanomaterials for Cardiac Arrhythmia and Future Directions in Bioevaluation Strategies | Advances in Conductive Nanomaterials for Cardiac Arrhythmia and Future Directions in Bioevaluation Strategies Abstract Abstract Cardiac arrhythmia (CA), characterized by irregular heart rhythms, affects nearly 90% of individuals with cardiovascular diseases. Commonly triggered by myocardial infarction (MI) or ion chann... |
PMC4318893 | core_pubmed_pmc | 11β-Hydroxysteroid Dehydrogenase Activity in the Brain Does Not Contribute to Systemic Interconversion of Cortisol and Cortisone in Healthy Men | 11β-Hydroxysteroid Dehydrogenase Activity in the Brain Does Not Contribute to Systemic Interconversion of Cortisol and Cortisone in Healthy Men Abstract Abstract Context and Objective: 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) catalyses regeneration of cortisol in liver, adipose tissue, and skeletal muscle, mak... |
PMC5357096 | core_pubmed_pmc | Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats | Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats Abstract Background: Although albendazole is the drug-of-choice for the treatment of neurocysticercosis, its efficacy is limited due to its low bioavailability. An alternative for optimizing pharmacological treatment is thr... |
PMC9747118 | core_pubmed_pmc | Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma | Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma Abstract Abstract The aims of this work were to develop a population pharmacokinetic (PK) model for chimeric antigen receptor (CAR) transgene after single intravenous infusion adminis... |
PMC4326208 | core_pubmed_pmc | Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery | Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery Abstract Abstract Background Unfractionated heparin (UFH) is widely used as a reversible anti-coagulant in cardiopulmonary bypass (CPB). However, the pharmacokinetic characteristics of UFH in CPB surgeries remain ... |
PMC10615937 | core_pubmed_pmc | Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11 | Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11 Abstract Abstract Belantamab mafodotin, a B-cell maturation antigen-targeting antibody–drug conjugate (ADC), was investigated in Japanese patients with relapsed/refract... |
PMC5760995 | core_pubmed_pmc | Method development and validation of Guanfacine in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study | Method development and validation of Guanfacine in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study Abstract Abstract A selective, sensitive and high-throughput liquid chromatography–tandem mass spectrometry (LC–ESI-MS/MS) method has been developed and validated for t... |
PMC7187627 | core_pubmed_pmc | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota | Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota Abstract CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile , inhibiting C. di... |
PMC3463859 | core_pubmed_pmc | Integrating Experimentation and Quantitative Modeling to Enhance Discovery of Beta Amyloid Lowering Therapeutics for Alzheimer’s Disease | Integrating Experimentation and Quantitative Modeling to Enhance Discovery of Beta Amyloid Lowering Therapeutics for Alzheimer’s Disease Abstract Abstract Drug discovery can benefit from a proactive-knowledge-attainment philosophy which strategically integrates experimentation and pharmacokinetic/pharmacodynamic (PK/PD... |
PMC3131558 | core_pubmed_pmc | Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis | Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis Abstract Abstract Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events ... |
PMC4326489 | core_pubmed_pmc | Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model | Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model Abstract Abstract Background Even though malaria is a completely preventable and treatable disease, it remains a threat to human life and a burden to the global economy due to the emergence of multiple-drug resistant mala... |
PMC11106956 | core_pubmed_pmc | Population pharmacokinetics of primaquine and its metabolites in African males | Population pharmacokinetics of primaquine and its metabolites in African males Abstract Background Primaquine (PQ) is the prototype 8-aminoquinoline drug, a class which targets gametocytes and hypnozoites. The World Health Organization (WHO) recommends adding a single low dose of primaquine to the standard artemisinin-... |
PMC3610115 | core_pubmed_pmc | Study of the pharmacokinetic changes of Tramadol in diabetic rats | Study of the pharmacokinetic changes of Tramadol in diabetic rats Abstract Abstract Background Besides the pathological states, diabetes mellitus may also alter the hepatic biotransformation of pharmaceutical agents. It is advantageous to understand the effect of diabetes on the pharmacokinetic of drugs. The objective ... |
PMC11404262 | core_pubmed_pmc | Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial | Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial Abstract Abstract Introduction Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage ... |
PMC9712457 | core_pubmed_pmc | Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation | Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation Abstract Abstract Objective: To study the potential targets and molecular mechanisms of Fritiliariae Irrhosae Bulbus (FIB) in the treatment of ischemic strokes based on a networ... |
PMC5247555 | core_pubmed_pmc | Pharmacokinetics, Biotransformation, and Excretion of [ 14 C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis | Pharmacokinetics, Biotransformation, and Excretion of [ 14 C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis Abstract Abstract Etelcalcetide (AMG 416) is a novel synthetic peptide calcium-sensing receptor activator in clinical development a... |
PMC7838024 | core_pubmed_pmc | A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect | A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect Abstract Liposomes have made remarkable achievements as drug delivery vehicles in the clinic. Liposomal products mostly benefited from remote drug loading techniques that succ... |
PMC10175964 | core_pubmed_pmc | A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults | A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults Abstract Abstract Vupanorsen (PF‐07285557) is a second‐generation tri‐ N ‐acetyl galactosamine (GalNAc 3 )‐antisense oligonucleotide targeted to angiopoietin‐like 3 (ANGP... |
PMC9457773 | core_pubmed_pmc | Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats | Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats Abstract Abstract Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibit... |
PMC4112050 | core_pubmed_pmc | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates Abstract Abstract Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising the humanized... |
PMC12129583 | core_pubmed_pmc | A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar? | A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar? Abstract Abstract Objectives To assess the c... |
PMC4432908 | core_pubmed_pmc | Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration | Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration Abstract Background Intravenous anaesthetic drugs are the primary means for producing general anaesthesia in equine practice. The ideal drug for intravenous anaesthesia has high reliability an... |
PMC10405310 | core_pubmed_pmc | Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial | Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial Abstract Summary Background Pediatric patients with certain rare diseases are at increased risk of severe respiratory s... |
PMC9135659 | core_pubmed_pmc | Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial | Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial Abstract Abstract Aim: To assess the results of a phase I/IIa open-label dose-escalation clinical trial of 5-day repeated intramuscular administration of pitavastatin-incorporated poly (lactic-co-glycolic acid) n... |
PMC12155186 | core_pubmed_pmc | GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives | GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives Abstract Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of metabolic disorders, have recently emerged as promising candidates for the management of substance use disorders. This revie... |
PMC9075506 | core_pubmed_pmc | A selective and sensitive UFLC-MS/MS method for the simultaneous determination of five alkaloids from Piper longum L. and its application in the pharmacokinetic study of 6-OHDA-induced Parkinson's disease rats | A selective and sensitive UFLC-MS/MS method for the simultaneous determination of five alkaloids from Piper longum L. and its application in the pharmacokinetic study of 6-OHDA-induced Parkinson's disease rats Abstract Abstract The alkaloids from Piper longum L. (PLA) mainly contain piperine (PPR), piperlongumine (PPL)... |
PMC11179669 | core_pubmed_pmc | Enhanced Pharmacokinetics of Celastrol via Long-Circulating Liposomal Delivery for Intravenous Administration | Enhanced Pharmacokinetics of Celastrol via Long-Circulating Liposomal Delivery for Intravenous Administration Abstract Abstract Background Rheumatoid Arthritis (RA) involves prolonged inflammation of the synovium, damaging joints and causing stiffness and deformity. Celastrol (Cel), derived from the Chinese herbal medi... |
PMC2805799 | core_pubmed_pmc | Dosage and formulation issues: oral vitamin E therapy in children | Dosage and formulation issues: oral vitamin E therapy in children Abstract Purpose Oral vitamin E is used in several childhood diseases, but dosage recommendations differ. Few oral products have a marketing authorization for therapeutic use in children. Preliminary data indicate differences in bioavailability among the... |
PMC5190058 | core_pubmed_pmc | Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application | Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application Abstract Breast cancer is a major global health problem with high incidence and case fatality rates. The use of magnetoliposomes has b... |
PMC10534335 | core_pubmed_pmc | Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC) | Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC) Abstract Abstract Non-small-cell lung cancer (NSCLC) mortality and new case rates are both on the rise. Most patients have fewer treatment options accessible due to side effects from drugs and the emergenc... |
PMC10855066 | core_pubmed_pmc | Anti-Inflammatory and Antioxidant Pyrrolo[3,4- d ]pyridazinone Derivatives Interact with DNA and Bind to Plasma Proteins—Spectroscopic and In Silico Studies | Anti-Inflammatory and Antioxidant Pyrrolo[3,4- d ]pyridazinone Derivatives Interact with DNA and Bind to Plasma Proteins—Spectroscopic and In Silico Studies Abstract Abstract From the point of view of the search for new pharmaceuticals, pyridazinone derivatives are a very promising group of compounds. In our previous w... |
PMC6226122 | core_pubmed_pmc | No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy | No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy Abstract Abstract We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK‐8742‐P010 and MK‐5172‐P03... |
PMC4211354 | core_pubmed_pmc | Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae : Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012 | Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae : Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012 Abstract Antibiotic susceptibility breakpoints are determined at the time of clinical approval for a given drug, but may need to be revised to ... |
PMC4776683 | core_pubmed_pmc | The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study | The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study Abstract Abstract Purpose : Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regiona... |
PMC6351946 | core_pubmed_pmc | Breast Cancer and Exposure to Organochlorines in the CECILE Study: Associations with Plasma Levels Measured at the Time of Diagnosis and Estimated during Adolescence | Breast Cancer and Exposure to Organochlorines in the CECILE Study: Associations with Plasma Levels Measured at the Time of Diagnosis and Estimated during Adolescence Abstract Exposure to environmental chemicals with hormonal effects, such as organochlorine compounds (OCs), during developmental periods of breast cells m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.